评估靶向表皮生长因子受体抑制剂对局部上尿路上皮癌耐受性和活性的 1b 期试验

The Journal of Urology Pub Date : 2024-04-04 DOI:10.1097/ju.0000000000003928

Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Rhenita Amirtharaj, Lianchun Xiao, Suzanne Lange, Dzifa Y Duose, Shufang Wang, Sumanta Pal, Matthew T Campbell

{"title":"评估靶向表皮生长因子受体抑制剂对局部上尿路上皮癌耐受性和活性的 1b 期试验","authors":"Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Rhenita Amirtharaj, Lianchun Xiao, Suzanne Lange, Dzifa Y Duose, Shufang Wang, Sumanta Pal, Matthew T Campbell","doi":"10.1097/ju.0000000000003928","DOIUrl":null,"url":null,"abstract":"We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"117 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma.\",\"authors\":\"Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Rhenita Amirtharaj, Lianchun Xiao, Suzanne Lange, Dzifa Y Duose, Shufang Wang, Sumanta Pal, Matthew T Campbell\",\"doi\":\"10.1097/ju.0000000000003928\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations.\",\"PeriodicalId\":501636,\"journal\":{\"name\":\"The Journal of Urology\",\"volume\":\"117 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/ju.0000000000003928\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ju.0000000000003928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

我们针对局部上尿路上皮癌（UTUC）患者启动了一项基于生物标记物的术前研究，研究对象是成纤维细胞生长因子受体（FGFR）抑制剂 infigratinib。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma.

We initiated a biomarker-informed preoperative study of infigratinib, a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Journal of Urology

自引率

0.00%

发文量